Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole
about
Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasionThe Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer.Prognostic significance of minichromosome maintenance proteins in breast cancerEarly operable breast cancer in elderly women treated with an aromatase inhibitor letrozole as sole therapy.The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistancePreclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERα-Positive Breast Cancer.Understanding the mechanisms of aromatase inhibitor resistance.Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer.Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer.AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studiesEffects of In Utero Exposure to Ethinyl Estradiol on Tamoxifen Resistance and Breast Cancer Recurrence in a Preclinical Model.Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitNeoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxelThe prognostic significance of Cdc6 and Cdt1 in breast cancer.LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome.EGR1 regulates cellular metabolism and survival in endocrine resistant breast cancer.Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy.Antihormone induced compensatory signalling in breast cancer: an adverse event in the development of endocrine resistance.Curated compendium of human transcriptional biomarker data.Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancerBCMA (TNFRSF17) Induces APRIL and BAFF Mediated Breast Cancer Cell StemnessEndocrine Resistance in Breast Cancer
P2860
Q27342622-9BBC8103-68C6-43C3-B7EF-E4C575276070Q30978083-B11C17AF-EDD9-4307-A6D1-01DA7895485CQ33688564-84202E67-DBCD-4671-B6E9-C2071F26E38AQ33885064-5545BBE7-CB3C-4680-9902-F60400FEFBCBQ34991337-C1FBAD29-CD26-44AA-BC10-46A18BAC518BQ35653956-BF39C02B-A2FA-4750-8A59-59FB97FE4344Q36013029-AB743C8B-7E90-4C05-8586-A6F2AE395ABFQ36245376-26BB31AF-828D-407F-B138-40D38618AAC3Q36296553-8ED0D3EB-B836-4A18-869A-5A39512BA62AQ36393053-46CD7618-A983-47BF-86CA-2EC99B287CA8Q36557683-231E850D-E296-4458-8494-65E27701E1C0Q36782224-FFC546E4-D759-4E9A-B227-086FADC07D61Q37247518-656360BD-9F7D-43D8-83EC-70483C89024AQ38747536-8A0D087F-F508-4A53-9673-EA005C43477EQ38818289-153D6A9F-4F57-494B-9452-DAAFFB4DA54CQ39172020-647E068B-C5DA-4E36-B687-1C6E31C68724Q39375196-287D0EFD-495A-4D93-9A6E-00EC97F23DADQ41140406-89CDC450-4016-4B11-A3A5-32EB5C13DB74Q41950020-AEB4F9F3-72AC-4874-A0D4-F6EB75BECF54Q42282812-7422A97D-DEC5-4466-BFDC-CF62FBB4FCF0Q47122770-F849D1C4-C774-41F9-9D05-4CF94F388561Q47162938-B3AC6031-35FF-485F-9133-3370AB3DAFEAQ54610139-036FAF83-92D8-455C-95EE-CF9847B7AB20Q55039669-F6A6C2D9-AC18-476F-B0DF-6C780578EC8DQ58765163-4996DB8C-3A08-4D5C-8B21-3A19DAC880F2Q58797150-EE27D411-1B39-497B-A924-EB2FCBDA11B2Q59072640-B2B2152B-B018-4618-84B1-61E786F497AB
P2860
Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Changes in expression of oestr ...... aromatase inhibitor, letrozole
@ast
Changes in expression of oestr ...... aromatase inhibitor, letrozole
@en
Changes in expression of oestr ...... aromatase inhibitor, letrozole
@nl
type
label
Changes in expression of oestr ...... aromatase inhibitor, letrozole
@ast
Changes in expression of oestr ...... aromatase inhibitor, letrozole
@en
Changes in expression of oestr ...... aromatase inhibitor, letrozole
@nl
prefLabel
Changes in expression of oestr ...... aromatase inhibitor, letrozole
@ast
Changes in expression of oestr ...... aromatase inhibitor, letrozole
@en
Changes in expression of oestr ...... aromatase inhibitor, letrozole
@nl
P2860
P356
P1476
Changes in expression of oestr ...... aromatase inhibitor, letrozole
@en
P2093
William R Miller
P2860
P2888
P356
10.1186/BCR2611
P577
2010-07-20T00:00:00Z
P5875
P6179
1003636949